Evidence map›Paper›PMID 38049990›Full record

ArticleAJNR. American journal of neuroradiology2023

T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy.

Mark Behar, Kyung K Peck, Onur Yildirim, Jamie Tisnado, Atin Saha, Julio Arevalo-Perez, Eric Lis, Yoshiya Yamada, Andrei I Holodny, Sasan Karimi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AJNR. American journal of neuroradiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Mark BeharFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8193-4686
Kyung K PeckFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9841-3078
Onur YildirimFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1586-1933
Jamie TisnadoFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1608-3595
Atin SahaFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8446-6315
Julio Arevalo-PerezFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6283-0558
Eric LisFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4138-3867
Yoshiya YamadaDepartment of Radiation Oncology (Y.Y.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1212-2331
Andrei I HolodnyFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York holodnya@mskcc.org.ORCID 0000-0002-1159-2705
Sasan KarimiFrom the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5913-3551
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

background and purposeCurrent imaging techniques have difficulty differentiating treatment success and failure in spinal metastases undergoing radiation therapy. This study investigated the correlation between changes in dynamic contrast-enhanced MR imaging perfusion parameters and clinical outcomes following radiation therapy for spinal metastases. We hypothesized that perfusion parameters will outperform traditional size measurements in discriminating treatment success and failure. MATERIALS AND

methodsThis retrospective study included 49 patients (mean age, 63 [SD, 13] years; 29 men) with metastatic lesions treated with radiation therapy who underwent dynamic contrast-enhanced MR imaging. The median time between radiation therapy and follow-up dynamic contrast-enhanced MR imaging was 62 days. We divided patients into 2 groups: clinical success (

resultsThe reduction in plasma volume was greater in the success group than in the failure group (-57.3% versus +88.2%, respectively;

conclusionsThe specificity of plasma volume was higher than that of conventional size measurements, suggesting that dynamic contrast-enhanced MR imaging is a powerful tool to discriminate between treatment success and failure.

Indexed as

Brain NeoplasmsSpinal NeoplasmsContrast MediaHumansMagnetic Resonance ImagingMaleMiddle AgedPerfusion ImagingRetrospective StudiesSensitivity and SpecificityContrast Media

Identifiers

PMID38049990
PMCPMC10714859
OpenAlexW4389167457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.